Kearon study - description and results

first episode of idiopathic venous thromboembolism; DVT demonstrated by bilateral compression ultrasonography of the proximal leg veins, and (if possible) bilateral impedance plethysmography; PE by ventilation-perfusion lung scan;

Exclusion criteria

other indications for, or contraindication to, long-termanticoagulant therapy; need for long-term treatment with nonsteroidal anti-inflammatory drugs, ticlopidine, sulfinpyrazone, dipyridamole, or more than 160 mg of aspirin per day; familial bleeding disorder; major psychiatric disorder; pregnant or could become pregnant

Baseline characteristics

time of randomization

1 months

Method and design

Randomized effectives

NA / NA (studied vs. control)

Design

Parallel groups

Blinding

double blind

Follow-up duration

11 months (after randomizatio)

Number of centre

Geographic area

Canada, US

Primary endpoint

recurrent VTE

Reference(s)

Trials register #

Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, Mackinnon B, Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kahn SR, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor.. J Thromb Haemost 2004;2:743-9

Pubmed | Hubmed | Fulltext

Kearon study, 2004

Treatments

Patients

Method and design

Results

Reference(s)